Development of a Microvessel Density Gene Signature and Its Application in Precision Medicine
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
A novel gene signature for MVD was developed. This MVD gene score enables the estimation of MVD, reflecting the sensitivity to antiangiogenic inhibitors, in transcriptomic datasets. We demonstrated the utility of the MVD gene score together with a T cell-inflamed gene signature for potential future use as a clinical biomarker.
References
1.
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D
. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940.
PMC: 5531419.
DOI: 10.1172/JCI91190.
View
2.
Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T
. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14):1289-1300.
DOI: 10.1056/NEJMoa2035716.
View
3.
Uhlik M, Pointing D, Iyer S, Ausec L, Stajdohar M, Cvitkovic R
. Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers. Front Oncol. 2023; 13:1158345.
PMC: 10213262.
DOI: 10.3389/fonc.2023.1158345.
View
4.
Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T
. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2007; 122(3):664-71.
DOI: 10.1002/ijc.23131.
View
5.
Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, de Castro Jr G
. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928.
DOI: 10.1016/S0140-6736(19)32591-7.
View